Agents and Actions

, Volume 3, Issue 5, pp 348–356 | Cite as

Anti-inflammatory mechanism of inflamed-tissue factor

  • I. L. Bonta
  • J. Noordhoek
Selected Papers


The early postulation that irritation of tissue could release a substance which acted as anti-inflammatory agent at a remote site of the body, led further to show that administration of inflammatory exudate results in suppression of experimental inflammations (Rindani [22], Robinson and Robson [23], Billingham, Robinson and Robson [2], Bonta and De Vos [6]). Little is known however as to which type of inflammatory response is preferentially inhibited by inflammed-tissue factors(s) and even less is known the mechanism associated with this inhibition. Earlier we studied the anti-inflammatory effect of exudates from peritoneal inflammation, but in later experiments we made use of exudates obtained from aircarrageenin granuloma pouches of rats (Bonta, Bhargava and De Vos [7]). The dialysate of the exudate showed only potency in suppressing the kaolin induced hind paw inflammation of the rat. A marked and dose dependent inhibition of this inflammation was however found with the retentate. The anti-inflammatory macromolecular (mol wt 200,000) portion of the exudate is a complexity of proteins and may be other materials. The macromolecular factor(s) obtained from donor rats did also suppress the kaolin induced hind paw inflammation when administered to mice, herewith ruling out species-specificity. The anti-inflammatory effect of the exudate was not diminished by adrenalectomy of the test-animals, thus excluding the discharge of corticosteroids as a conceivable mechanism. The macromolecular retentate did not only cause inhibition of the kaolin induced inflammation, but the carrageenin-inflammation in rats was also suppressed. On the other hand the inflammatory response by histamine or serotonin was not inhibited by the pouch-exudate, which thus apparently displays a preferential inhibition of certain type of inflammations while leaving others unaffected (Bonta, Bhargava and De Vos [7]). We found no indications that the anti-inflammatory effect of the exudate factor(s) was mediated through either influencing the kininogen-kinin system or interfering with prostaglandins as putative inflammatory mediators. However depletion of complement was evident in the carrageenin induced inflammation, representing the type of response which is sensitive to the anti-inflammatory effect by the pouchexudate. In line with this we have data that the exudate inhibits total complement activity of serum when either added in vitro or administered in vivo. The complement inhibitory property of the exudate seemed to parallel with the anti-inflammatory activity. Complement fixation has been proposed as the underlying mechanism of the counterirritant principle (Willoughby, Coote and Turk [26]), which in fact was the early starting point to investigate the anti-inflammatory effect of exudates obtained from irritated tissue. It is however, not likely that tissue irritation due to injection of our macromolecular factor is the exclusive mode in its anti-inflammatory effect. In fact we observed the anti-inflammatory effect even after intravenous administration, which largely rules out local tissue irritation. Complement inhibition appears to be a common pathway in the anti-inflammatory effect of the counter-irritant principle and of inflammed-tissue factor(s). The latter may however induce this effect without counter-irritation. Furthermore complement inhibition does not exclude the participation of other conceivable mechanisms (e.g. lysosomal membrane stabilization) in the anti-inflammatory effect of the inflamed-tissue exudate, which most likely contains more than one active factor.


Kaolin Dose Dependent Inhibition Lysosomal Membrane Complement Fixation Conceivable Mechanism 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    D.C. Atkins, A.L.A. Boura andR. Hicks, Eur. J. Pharmac.8, 348 (1969).CrossRefGoogle Scholar
  2. [2]
    M.E.J. Billingham, B.V. Robinson andJ.M. Robson, Br. J. Pharmac.35, 543 (1969a).Google Scholar
  3. [3]
    M.E.J. Billingham, B.V. Robinson andJ.M. Robson, Br. med. J.2, 93 (1969b).PubMedGoogle Scholar
  4. [4]
    M.E.J. Billingham, A.H. Gordon andB.V. Robinson, Nature New Biol.231, 26 (1971).PubMedGoogle Scholar
  5. [5]
    I.L. Bonta andC.J. De Vos, Eur. J. Pharmac.1, 222 (1967).CrossRefGoogle Scholar
  6. [6]
    I.L. Bonta andC.J. De Vos, in: Proc. Int. Symp. Inflamm. Biochem. Drug Interact (Eds J.C. Houck and A. Bertelli; Excerpta Med. Found., Amsterdam 1969), p. 103.Google Scholar
  7. [7]
    I.L. Bonta, N. Bhargava andC.J. De Vos, Experientia26, 759 (1970).PubMedGoogle Scholar
  8. [8]
    A. Boris andR.H. Stevenson, Arch. int. Pharmacodyn.153, 205 (1965).Google Scholar
  9. [9]
    P. Crunkhorn andS.C.R. Meacock, Br. J. Pharmac.42, 392 (1971).Google Scholar
  10. [10]
    G. DiPasquale andR.J. Girerd, Am. J. Physiol.201, 1155 (1961).PubMedGoogle Scholar
  11. [11]
    M. Di Rosa, J.P. Giroud andD.A. Willoughby, J. Path.104, 15 (1971).CrossRefPubMedGoogle Scholar
  12. [12]
    V. Eisen andC. Loveday, Br. J. Pharmac.42, 383 (1971).Google Scholar
  13. [13]
    C.H. Gillies,The Theory and Practice of Counter-Irritation (MacMillan and Co. Publ., London 1895).Google Scholar
  14. [14]
    M.W. Greaves andJ. Sondergaard, J. invest. Derm.54, 365 (1970).CrossRefPubMedGoogle Scholar
  15. [15]
    T.C. Highton, Br. J. exp. Pathol.44, 137 (1963).PubMedGoogle Scholar
  16. [16]
    J.T. Hitchens, S. Goldstein, I. Shemano andJ.M. Beiler, Arch. int. Pharmacodyn.169, 384 (1967).PubMedGoogle Scholar
  17. [17]
    C. Laden, Q.R. Blackwell andL.S. Fosdick, Am. J. Physiol.195, 712 (1958).PubMedGoogle Scholar
  18. [18]
    J. Noordhoek andI.L. Bonta, Arch. int. Pharmacodyn.197 385 (1972).PubMedGoogle Scholar
  19. [19]
    A.G. Osler, I.H. Strauss andM.M. Mayer, Am. J. Syph. Gonorrhea vener. Dis.36, 140 (1952).PubMedGoogle Scholar
  20. [20]
    H.E. Paulus andM.W. Whitehouse, in:Search for New Drugs, (Ed. A. Rubin; M. Dekker Inc., New York 1972), p. 1.Google Scholar
  21. [21]
    H.E. Paulus andM.W. Whitehouse Non Steroid Anti-Inflammatory Agents, Ann Rev. Pharmac., in press (1973).Google Scholar
  22. [22]
    T.H. Rindani, Ind. J. Med. Res.44, 673 (1956).Google Scholar
  23. [23]
    B.V. Robinson andJ.M. Robson, Br. J. Pharmac.26, 372 (1966).Google Scholar
  24. [24]
    M. Rocha e Silva, R.Q. Cavalcanti andM.L. Reis, Biochem. Pharmac.18, 1285 (1969).CrossRefGoogle Scholar
  25. [25]
    P.A. Ward andC.G. Cochrane, J. exp. Med.121, 215 (1965).CrossRefPubMedGoogle Scholar
  26. [26]
    D.A. Willoughby, E. Coote, andJ.L. Turk, J. Path.97, 295 (1969).CrossRefPubMedGoogle Scholar
  27. [27]
    D. Winne, Arzneimittel-Forsch.14, 1290 (1964).Google Scholar

Copyright information

© Birkhäuser Verlag 1973

Authors and Affiliations

  • I. L. Bonta
    • 1
  • J. Noordhoek
    • 1
  1. 1.Department of Pharmacology, School of MedicineErasmus UniversityRotterdamThe Netherlands

Personalised recommendations